The Clinical Trial Application for SGB-3908 for the Treatment of Hypertension Has Been Accepted by the China Center for Drug Evaluation
May 8, 2024
BOSTON, SHANGHAI, and SUZHOU – May 8, 2024, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that the clinical trial application of SGB-3908 injection, an experimental drug candidate for the treatment of hypertension, has recently been officially accepted by the China Center for Drug Evaluation (CDE) of the National Medical Products Administration.
SGB-3908 is an RNAi-based experimental medicine drug targeting Angiotensinogen (AGT) for the treatment of hypertension. Preclinical data demonstrated that SGB-3908 significantly reduced AGT protein and related biomarkers including ANG I and ANG II in the serum of cynomolgus monkeys with hypertension, achieving a significant long-term antihypertensive efficacy without safety issues such as low blood pressure. SGB-3908 utilizes SanegeneBio's proprietary siRNA platform technology, and displays industry-leading potency, durability, safety and tolerability in preclinical models.
said Dr. Weimin Wang, Founder and Chief Executive Officer of SanegeneBio.
About Hypertension
Hypertension is a common chronic disease that currently affects over 1 billion people worldwide. It not only increases the risk of cardiovascular and cerebrovascular diseases while also potentially leads to complications such as kidney damage and impaired vision. With the aging population and the rising prevalence of risk factors such as obesity, lack of physical exercise, and unhealthy diet, the incidence of hypertension is still increasing globally. There are effective anti-hypertension treatments in clinical practice, however, these treatments have some disadvantages. For example the anti-hypertension drugs need to be taken every day, and hypertension is difficult to perceive when symptoms are not severe, which can lead to noncompliance in taking medicines. Poor compliance has become a major challenge in the treatment of hypertension, with less than 20% of hypertension patients achieving long-term effective control. As an alternative solution to address this challenge in the treatment of hypertension, siRNA drugs can directly knockdown the expression of AGT, with the advantages of long efficacy duration, good safety, and high compliance, thus is expected to bring better treatment options and long-term benefits to the hypertensive patients.
About SGB-3908
SGB-3908, an siRNA-GalNAc conjugate targeting Angiotensinogen (AGT) for the treatment of hypertension, is delivered to liver using SanegeneBio's novel GalNAc platform to inhibit the synthesis of AGT in the liver through RNA interference. SGB-3908 can inhibit the synthesis of AGT in the liver, potentially leading to durable reductions of AGT protein, further causing a decrease in angiotensin (Ang) II, and ultimately resulting in vasodilation and lowering blood pressure. In December 2023, SanegeneBio and Innovent jointly announced that they entered into a collaboration agreement to co-develop SGB-3908, and Innovent obtained an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908 in different regions.
About AGT
AGT is the upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), a cascade which has demonstrated function in blood pressure regulation, and the inhibition of AGT has shown well-established anti-hypertension effects.
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021, SanegeneBio is led by a team of RNAi pioneers with unrivaled experience in this Nobel Prize-winning technology. With R&D operations in Boston, Shanghai and Suzhou, our vision clear – RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for countless patients in the coming years. Our fast-growing pipeline includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for several experimental medicines, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage with us on LinkedIn.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. Any statements in this release other than statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "could," "potential," "is/are likely to," "will," "plan," "intend," "aim," "expect," "anticipate," "believe," "hope," "estimate," "project," "forecast," "continue," "target," and similar expressions (or the negative of these terms) are intended to identify forward-looking statements. In addition, statements that refer to future results, trends in our business, expectations for our product pipeline or product candidates, or other characterizations of future events or circumstances are forward-looking statements.
These forward-looking statements are based on our current expectations and assumptions as of the date of this news release and speak only as of such date. They are not guarantees of future performance, and actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of risks and uncertainties, many of which are beyond our control. These risks and uncertainties include, without limitation: risks in research and development and clinical trials; regulatory review, requirements, and timing; trial initiation, site activation, enrollment, and operational execution (including performance by third parties); manufacturing, supply, and quality risks; the impact of competition and new technologies; future market conditions; macroeconomic, political, legal, and social conditions; and our ability to obtain and maintain sufficient funding and other resources. Readers are cautioned not to place undue reliance on these forward-looking statements. We assume no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by applicable law.
Medical Information
This press release is provided for informational purposes only and is intended to share scientific and disease-related information. It is not intended as advertising or commercial promotion of any product and does not constitute medical advice, a diagnosis, or a recommendation for any treatment or use of any product. For questions about medical conditions or treatment, please seek advice from a healthcare professional.